BidaskClub Upgrades Atara Biotherapeutics (ATRA) to Strong-Buy

BidaskClub upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a buy rating to a strong-buy rating in a research note published on Tuesday.

Other equities research analysts have also issued research reports about the stock. William Blair reissued a buy rating on shares of Atara Biotherapeutics in a research note on Friday, April 6th. ValuEngine raised shares of Atara Biotherapeutics from a hold rating to a buy rating in a research note on Monday, April 2nd. Canaccord Genuity reissued a buy rating and set a $70.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, March 13th. Jefferies Group boosted their price objective on shares of Atara Biotherapeutics from $30.00 to $46.00 and gave the stock a buy rating in a research note on Monday, March 5th. Finally, Zacks Investment Research raised shares of Atara Biotherapeutics from a hold rating to a buy rating and set a $45.00 price objective on the stock in a research note on Tuesday, May 1st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $42.50.

NASDAQ:ATRA opened at $50.20 on Tuesday. Atara Biotherapeutics has a one year low of $11.80 and a one year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.13). research analysts expect that Atara Biotherapeutics will post -4.06 earnings per share for the current year.

In other news, EVP Christopher Haqq sold 18,327 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $39.79, for a total value of $729,231.33. Following the transaction, the executive vice president now owns 334,005 shares in the company, valued at $13,290,058.95. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Derrell Porter sold 1,544 shares of the company’s stock in a transaction that occurred on Tuesday, May 8th. The stock was sold at an average price of $40.15, for a total transaction of $61,991.60. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at approximately $501,875. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,671 shares of company stock worth $6,675,042. Insiders own 10.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James & Associates lifted its stake in shares of Atara Biotherapeutics by 7.3% in the fourth quarter. Raymond James & Associates now owns 25,325 shares of the biotechnology company’s stock worth $458,000 after buying an additional 1,719 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of Atara Biotherapeutics by 4.6% in the fourth quarter. California State Teachers Retirement System now owns 42,159 shares of the biotechnology company’s stock worth $763,000 after buying an additional 1,836 shares in the last quarter. Riverhead Capital Management LLC bought a new position in shares of Atara Biotherapeutics in the first quarter worth approximately $100,000. SG Americas Securities LLC bought a new position in shares of Atara Biotherapeutics in the first quarter worth approximately $107,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Atara Biotherapeutics by 13.3% in the first quarter. The Manufacturers Life Insurance Company now owns 24,505 shares of the biotechnology company’s stock worth $955,000 after buying an additional 2,881 shares in the last quarter.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply